DeepMed Research

Flotetuzumab

Generic Name: Flotetuzumab

Drug Type: Biotech

CAS Number: 1664355-28-5

Unique Ingredient Identifier: 0AHT0IC02G

Background: Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).

Clinical Trials

Post-transplant Flotetuzumab for AML

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Flotetuzumab

First Posted Date: 2022-08-18

Last Posted Date: 2024-08-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT05506956

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Study to Assess an Interphase Cycle With Flotetuzumab.

Phase 2

Withdrawn

Conditions: AML

Interventions: Drug: Flotetuzumab

First Posted Date: 2021-09-30

Last Posted Date: 2021-12-22

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Registration Number: NCT05063123

Locations: 🇳🇱
NL-Groningen-UMCG, Groningen, Netherlands
🇳🇱
NL-Rotterdam-ErasmusMC, Rotterdam, Netherlands
🇳🇱
NL-Amsterdam-VUMC, Amsterdam, Netherlands

and more 1 locations

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Hairy Cell Leukemia
Refractory Hematologic Malignancy
Refractory Hodgkin Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Systemic Mastocytosis

Interventions: Drug: Acetaminophen
Drug: Dexamethasone
Drug: Diphenhydramine
Biological: Flotetuzumab
Drug: Ibuprofen
Drug: Ranitidine

First Posted Date: 2020-12-23

Last Posted Date: 2024-12-31

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 13

Registration Number: NCT04681105

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Phase 2

Terminated

Conditions: Relapsed Acute Myeloid Leukemia

Interventions: Drug: Flotetuzumab
Procedure: Donor lymphocyte infusion

First Posted Date: 2020-10-12

Last Posted Date: 2024-12-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 11

Registration Number: NCT04582864

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Flotetuzumab

First Posted Date: 2019-11-12

Last Posted Date: 2025-01-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 16

Registration Number: NCT04158739

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy